AKT1 and neoplasm: Indeed, clinical studies highlight the critical role of AKT signaling in the emergence of antiandrogen resistance and tumor progression in mCRPC, and a recent phase II study showed that combination of AKT inhibitor ipatasertib (upstream of mTOR and TLK1B) with abiraterone prolongs progression-free survival in mCRPC patients compared to abiraterone alone [36].